Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin vs Gemcitabine in Advanced Leiomyosarcoma
NCT04383119Phase 2Recruiting
- Sponsor
- Italian Sarcoma Group
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trabectedin in leiomyosarcoma (LMS) (3 arms), sponsored by Italian Sarcoma Group. Primary endpoint: Growth Modulation Index at 45 weeks. Started Oct 2021; status: recruiting.
02
Drugs
trabectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04383119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383119.